Introduction Cutting-edge clinical trials continue to reshape the treatment landscape in vascular surgery, metabolic health, and hematologic cancers. New data on Humacyte’s bioengineered vessels, Metsera’s amylin analog, and lisaftoclax in leukemia patients showcase the growing influence of biopharmaceutical innovation in meeting critical medical needs. Promising Results from Humacyte’s AV Access Study Humacyte has reported positive […]
